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864Allogeneic Hematopoietic Cell Transplantation
in Human Immunodeficiency Virus–Positive Patients
with Hematologic Disorders: A Report from the Center
for International Blood and Marrow Transplant
Research
Vikas Gupta,1 Marcie Tomblyn,2 Tanya L. Pedersen,3 Harry L. Atkins,4 Minoo Battiwalla,5
Ronald E. Gress,6 Marilyn S. Pollack,7 Jan Storek,8 Jill C. Thompson,3 Pierre Tiberghien,9
Jo-Anne H. Young,2 Patricia Ribaud,10 Mary M. Horowitz,11 Armand Keating1The role of allogeneic hematopoietic cell transplantation (alloHCT) in human immunodeficiency virus (HIV)-
positive patients is not known. Using the Center for International Blood and Marrow Transplant Research da-
tabase, we retrospectively evaluated 23 HIV-positive patients undergoing matched sibling donor (n 5 19) or
unrelated donor (n5 4) alloHCTbetween 1987 and 2003. Themedian age at alloHCTwas 32 years. Indications
for alloHCTwere diverse and included malignant (n 5 21) and nonmalignant (n 5 2) hematologic disorders.
Ninepatients (39%) underwent transplantation after 1996, the approximate year that highly active antiretroviral
therapy became standard treatment. The median time to neutrophil engraftment was 16 days (range, 7 to 30
days), and the cumulative incidences of grade II-IVacute graft-versus-host disease (aGVHD) at 100 days, chronic
GVHD (cGVHD), and survival at 2 years were 30% (95% confidence interval [CI]5 14% to 50%), 28% (95%CI
5 12% to 48%), and 30% (95% CI5 14% to 50%), respectively. At a median follow-up of 59 months, 6 patients
were alive. Survival appears to be better in the patients undergoing alloHCTafter 1996; 4 of these 9 patients
survived, compared with only 2 of 14 those undergoing transplantation before 1996. These data suggest that
alloHCT is feasible for selected HIV-positive patients with malignant and nonmalignant disorders. Prospective
studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients.
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Both autologous and allogeneic hematopoietic cell
transplantation (HCT) are valid treatment options in
patients with malignant and nonmalignant hemato-
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treatment (HAART) is widely available [6].
HIV-positive patients often are excluded from
consideration for HCT because of concerns about
infections and other treatment-related complications.
Several recent reports have demonstrated the feasibil-
ity and curative potential of autologous transplanta-
tion for HIV-associated lymphomas in adults and
children, however [7-17]. Although initial reports of
allogeneic HCT (alloHCT) as a primary treatment
for HIV infection failed to demonstrate the benefit
of this approach, because of either recurrence of
HIV infection or treatment-related death [18-20], re-
cent anecdotal reports suggest that alloHCT may be
feasible and beneficial in HIV-positive patients with
hematologic malignancies [21-28]. The role of al-
loHCT in these patients has not been studied in a -
systematic fashion, however.
Performing alloHCT inHIV-positive patients pres-
ents several challenges, including significant exposure to
opportunistic infections before HCT, a high incidence
of concomitant infections (eg, viral hepatitis), complex
drug interactionsbetweenantiretroviral and transplanta-
tion-related medications, and the effects of HIV on T
cells, the bone marrow environment, and the cytokine
milieu. For these reasons, HIV infection might have an
effect on engraftment, regimen-related toxicity, graft-
versus-host disease (GVHD), infection risk, and survival.
We retrospectively evaluated 23 HIV-positive pa-
tients who underwent alloHCT between 1987 and
2003 and were reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR).
The study’s primary objective was to determine
the clinical outcomes of alloHCT in HIV-positive pa-
tients. Secondary objectives were to evaluate CD4
recovery and viral load (VL) in the posttransplantation
period.PATIENTS AND METHODS
The study was conducted by the CIBMTR’s Infec-
tion and ImmuneReconstitutionWorking Committee.
Between 1987 and 2003, 50 HIV-positive patients who
underwent alloHCT were reported to the CIBMTR.
After eligible patients were identified, the centers were
contacted to confirm HIV infection. A total of 31 pa-
tients treated at 21 centers were confirmed to be HIV-
positive.Of these, 8patientsundergoing transplantation
for primary treatment of HIV disease (n 5 5) or from
a syngeneic donor (n5 3) were excluded. The remain-
ing 23 patients, who received a graft from either
a matched sibling donor (n5 19) or an unrelated donor
(n5 4) for amalignant (n5 21) or nonmalignant (n5 2)
hematologic disorder, were analyzed. Additional
information was requested regarding the history of
HIV infection, opportunistic infections, antiretroviraltherapy, CD4 counts, and VL both pretransplantation
and posttransplantation.CIBMTR
A formal affiliation of the research division of the
NationalMarrowDonorProgram (NMDP)and the In-
ternational Bone Marrow Transplant Registry at the
Medical College ofWisconsin led to the establishment
of the CIBMTR in 2004. The CIBMTR is a working
group comprising more than 500 transplantation cen-
ters worldwide that voluntarily contribute data on allo-
geneic and autologous HCT recipients to a Statistical
Center at the Medical College of Wisconsin or the
NMDP Coordinating Center in Minneapolis. Partici-
pating centers register and provide basic information
on all consecutive transplantations, with compliance
monitored by onsite audits. Detailed demographic, dis-
ease, and transplantation characteristics and outcome
data are collected on a sample of registered patients, in-
cluding all unrelated donor transplantations facilitated
by the NMDP in the United States. Patients are fol-
lowed longitudinally, with yearly follow-up. Comput-
erized error checks, physician review of submitted
data, and onsite audits of participating centers ensure
data quality. The CIBMTR’s observational studies are
performed with a waiver of informed consent and in
compliance with HIPAA regulations, as determined
by the Institutional Review Board and the PrivacyOffi-
cer of the Medical College of Wisconsin.
Definitions and Endpoints
Conditioning regimens were defined asmyeloabla-
tive (MA) and nonmyeloablative (NMA) using the cri-
teria defined by the CIBMTR [29]. At the time of
-alloHCT, performance status (PS) was defined
according to the Karnofsky scale for patients age $16
years and according to the Lansky scale for those age
\16 years. Primary endpoints were engraftment, acute
and chronic GVHD (aGVHD, cGVHD), and overall
survival (OS). Engraftment was defined as the first of
3 consecutive posttransplantation days on which the
neutrophil count exceeded 500/mm3. aGVHD events
were any occurrence of grade II, III, or IV skin, gastro-
intestinal, or liver abnormalities fulfilling the Glucks-
berg criteria [30]. cGVHD events included symptoms
in any organ system fulfilling the criteria for limited
or extensive cGVHD [31]. For survival analyses, failure
was defined as death from any cause; surviving patients
were censored at the time of last follow-up.
Statistical Analysis
Probabilities of aGVHD and cGVHD were calcu-
lated using cumulative incidence curves to accommo-
date competing risks. The competing risk for GVHD
was death from any cause. Univariate probabilities of
Table 1. Patient, Disease, and Transplantation-Related
Characteristics
Characteristic n Evaluated n
Number of patients 23 23
Number of centers 17
Median age at alloHCT, years (range) 23 32 (9-43)
Age at alloHCT, years 23
# 20 3 (13%)
21-40 17 (74%)
> 40 3 (13%)
Male sex 23 18 (78%)
PS score at alloHCT 23
# 80 7 (30%)
> 80 16 (70%)
Patients with detailed HIV data 23 13 (57%)
Coinfection with hepatitis virus at alloHCT 10
Hepatitis B surface antigen positive 1 (10%)
Hepatitis C virus antibody positive 1 (10%)
Timing of diagnosis of HIV infection 13
Before diagnosis of disorder for alloHCT 4 (31%)
At the time of diagnosis of disorder for alloHCT 3 (23%)
After diagnosis of disorder of alloHCT 2 (15%)
Incidental detection during alloHCTworkup 4 (31%)
Opportunistic infections before alloHCT 13
Pneumocystis carinii pneumonia 2 (15%)
CMV 4 (31%)
Invasive fungal 1 (8%)
Mycobacteria 1 (8%)
Others 1 (8%)
Antiretroviral therapy before alloHCT 13
Patients undergoing transplantation before 1996 6
None 2 (33%)
Monotherapy 3 (50%)
Double therapy 1 (17%)
Patients undergoing transplantation after 1996 7
None 0
Monotherapy or double therapy 1 (14%)
Triple therapy 6 (86%)
Indication for alloHCT 23
Malignant
NHL 10 (43%)
Low-grade 1
Intermediate 4
High-grade 5
Acute leukemias 7 (30%)
Myelodysplastic syndrome/AML 5
Acute lymphoblastic leukemia 1
Biphenotypic acute leukemia 1
CML 4 (17%)
Nonmalignant 2 (9%)
Aplastic anemia 1
Inherited erythrocyte disorder 1
Median interval from diagnosis of blood
disorder to alloHCT, months (range)
23 10 (4-172)
Year of alloHCT 23
1987-1995 14 (61%)
1996-2003 9 (39%)
Graft type 23
Bone marrow 18 (78%)
Peripheral blood 5 (22%)
Donor type 23
HLA-identical sibling 19 (83%)
Matched unrelated 4 (17%)
Recipient/donor CMV status 23
+/+, +/-, or -/+ 19 (83%)
-/- 2 (9%)
Unknown 2 (9%)
Conditioning regimen 23
Myeloablative
CY + TBI ± others 9 (39%)
TBI ± others 3 (13%)
Bu + CY ± others 6 (26%)
(Continued )
Table 1. (Continued )
Characteristic n Evaluated n
Cy ± others 2 (9%)
Nonmyeloablative 3 (13%)
GVHD prophylaxis 23
CsA/FK-506 ± MTX 16 (70%)
MTX ± others 3 (13%)
T cell depletion 1 (4%)
Others 3 (13%)
Bu indicates, busulfan; CsA, cyclosporine; GVHD, graft-versus-host dis-
ease; HCT, hematopoietic cell transplantation; CMV, cytomegalovirus;
NHL, non-hodgkin leukemia; Cy, high-dose cyclophosphamide; FK-
506, tacrolimus; MTX, methotrexate.
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Estimates of standard error for the survival function
were calculated using Greenwood’s formula, and
95% confidence intervals (CIs) were constructed using
log-transformed intervals. Assessment of infections
used infection density, defined as the number of infec-
tious episodes per patient days at risk, to account for
multiple infections in single patients. Analyses were
conducted using SAS version 9.1 (SAS Institute,
Cary, NC). Data were updated as of July 2007.RESULTS
Patient and Donor Characteristics
Patient, HIV disease, hematologic disorder, and
transplantation-related characteristics are summarized
in Table 1. The median age of recipients at alloHCT
was 32 years (range, 9 to 43 years). Indications for
allografting were diverse and included NHL in 10
patients, AML/myelodysplastic syndrome (MDS) in
5 patients, acute lymphoblastic leukemia (ALL) in 1
patient, biphenotypic acute leukemia (AA) in 1 patient,
chronic myelogenous leukemia (CML) in 4 patients,
aplastic anemia in 1 patient, and inherited abnormality
of erythrocyte differentiation/function in 1 patient.
The donors were 19 HLA-identical siblings (83%)
and 4 matched unrelated donors (17%). The condi-
tioning regimen was MA in 20 patients (87%) and
NMA in 3 patients (13%). Cyclophosphamide (Cy)
in combination with either total body irradiation
(TBI; n 5 9) or busulfan (Bu; n 5 6) were the most
commonly used MA conditioning regimens (Table
1). Most patients (16/23; 70%) received cyclosporine
(CsA)-based GVHD prophylaxis with or without
methotrexate (MTX).
Nine patients (39%) underwent transplantation af-
ter 1996, the approximate time when HAART and VL
testing became standard practice. In this subset of
patients, the median age was 37 years (range, 30 to
43 years), and disease indications for alloHCT in-
cluded CML in 4 patients, NHL in 4 patients, and
AML in 1 patient. The donors were 6 HLA-identical
siblings (67%) and 3 matched unrelated donors
Table 2. Outcomes in HIV-Positive Patients Undergoing
AlloHCT for Malignant and Nonmalignant Hematologic
Disorders
Outcome n Evaluated n
Median days to neutrophil engraftment (range) 18 16 (7-30)
Cumulative incidence of grade II-IV acute
GVHD, probability (95% CI) at 100 days
23% 30% (14%-50%)
Cumulative incidence of chronic GVHD,
probability (95% CI)
23%
At 1 year 28% (12%-48%)
At 2 years 28% (12%-48%)
Episodes of infection posttransplantation
# 100 days
Culture-positive bacterial 10
Invasive fungal 1
Pnemocystis carinii pneumonia 0
CMV reactivation 3
Mycobacteria 0
Hepatitis B or C 1
Others 5
>100 days
Culture-positive bacterial 4
Invasive fungal 1
Pnemocystis carinii pneumonia 0
CMV reactivation 0
Mycobacteria 0
Hepatitis B or C 1
Others 2
Median follow-up of survivors, months (range) 6
Before 1996 (n 5 2) 75 (59-90)
After 1996 (n 5 4) 51 (23-74)
Overall survival, probability (95% CI) 23%
At 1 year 30% (14%-50%)
At 2 years 30% (14%-50%)
Primary cause of death 17%
Disease relapse 1 (6%)
Nonrelapse mortality
Regimen-related toxicities
Pulmonary toxicity 6 (35%)
Other organ toxicities 3 (19%)
Graft failure 1 (6%)
Infections 4 (24%)
GVHD 1 (6%)
Others 1 (6%)
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease..
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conditioning underwent transplantation after 1996.
Diagnosis and History of HIV Infection
Details regarding the diagnosis and treatment
history of HIV infection and infectious complications
before transplantation were provided for 13 patients
(57%). The diagnosis of HIV infection was made in 4
of these 13 patients (31%) before the diagnosis of the
hematologic disorder for which transplantation was
performed. Five patients were diagnosed with HIV
either at the time of diagnosis (n 5 3; 23%) or after
the diagnosis (n5 2; 15%) of the hematologic disorder,
and 4 patients (31%) were found to be HIV-positive
during the alloHCT workup. Eight of the 9 patients
undergoing transplantation after 1996 had detailed
HIV information available. Three of these 8 patients
were diagnosed with HIV before the onset of the
disease for which the transplantation was indicated;
the remaining 5 patients were diagnosed with HIV
concomitantly with the malignancy (n 5 3), between
the onset of malignancy and performance of alloHCT
(n5 1), or at the time of the alloHCT workup (n5 1).
Table 1 provides information on opportunistic infec-
tions before alloHCT in all 13 patients.
Antiretroviral Therapy
Information on antiretroviral therapy before
alloHCT was available for 13 patients. Of the 14
patients who underwent transplantation before 1996,
2 were not on antiretroviral therapy before or during
transplantation, and 4 received either monotherapy
with zidovudine (n 5 1) or didanosine (n 5 2) or dou-
ble therapy with didanosine and stavudine (n 5 1).
Data were not available on the remaining 8 patients
who underwent transplantation before 1996. Of the 9
patients undergoing transplantation after 1996, 7 had
available data on antiretroviral therapy. All but 1 pa-
tient was on triple therapy. Information was provided
that 2 patients had planned cessation of their antiretro-
viral therapy peritransplantation and the therapy was
restarted within 1 month posttransplantation.
Outcomes of AlloHCT in HIV-Positive Patients
Table 2 summarizes the outcomes of HIV-positive
patients who underwent alloHCT.
Engraftment
Eighteen of the 23 patients achieved neutrophil
engraftment, at a median of 16 days (range, 7 to 30
days). Three of the 5 patients who did not achieve
engraftment died very early (on days 2, 6, and 10)
because of regimen-related toxicity. One patient
treated with NMA conditioning and HLA-matched
unrelated donor bone marrow transplantation experi-
enced secondary graft failure.GVHD
Eight of the 23 patients developed grade II-IV
aGVHD (5 with grade II, 2 with grade III, and 1
with grade IV). The cumulative incidence of acute
GVHD grade II-IV was 30% (95% CI 5 14% to
50%) at 100 days (Figure 1A). The median time of on-
set of aGVHD was 16 days after alloHCT (range, 5 to
47 days). The cumulative incidence of cGVHD at 2
years was 28% (95% CI 5 12% to 48%) (Figure 1B).
Survival
In the 6 surviving patients, the median follow-up
was 59 months (range, 23 to 90 months). Kaplan-
Meie probabilities of survival were at 57% (95% CI
5 36% to 76%) at 100 days, 30% (95% CI 5 14%
to 50%) at 1 year, and 30% (95% CI 5 14% to
50%) at 2 years (Figure 2). Four of the 9 patients
who underwent transplantation after 1996 survived,
compared with only 2 of the 14 patients who under-
went transplantation before 1996. Primary causes of
0 10 20 30 40 50 60 70 80 90 100
0 12 24
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
A
B
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pr
ob
ab
ili
ty
Pr
ob
ab
ili
ty
Months After Transplant
Days After Transplant
Figure 1. Cumulative incidence of acute GVHD (A) and chronic GVHD (B) in 23 patients with HIV undergoing alloHCT.
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6 of the 12 patients receiving high-dose TBI-contain-
ing conditioning regimens died from pulmonary
toxicity.0%
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Figure 2. Overall survival of 23 HIV-positive patientsPosttransplantation Infections
Detailed data on infections in the posttransplanta-
tion period were available for 19 patients and are
summarized in Table 2. Culture-positive bacterial0%
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undergoing alloHCT for a hematologic disorder.
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were the 2 most common infection-related events.
The infection density for the entire cohort was 1.16
infections per patient during the first 100 days.
When analyzed by transplantation period, the infec-
tion density in the first 100 days was 0.95 per patient
in those who underwent transplantation before 1996
and 1.43 per patient in those who underwent trans-
plantation after 1996.
CD4 Counts and VL
Information on CD4 counts was available for 9
patients, and 7 had data available on both pretrans-
plantation and posttransplantation counts. Among
8 patients with available pretransplantation CD4
counts, the median CD4 count was 173/mL (range,
0 to 1200/mL) at a median of 24 days (range, 11 to 65
days) before transplantation.At 1monthposttransplan-
tation, the median CD4 count was 38/mL (range, 0 to
370/mL).At 1 year posttransplantation, theCD4counts
in the 3 patients assessed were 640, 302, and 503/mL.
VL data were submitted for 6 patients, although
both pretransplantation and posttransplantation
values were available for only 4 patients. Pretransplan-
tation, 4 patients had no detectable virus; the remain-
ing patient had 3.6 log copies. In the 5 patients with
available data, the median VL was 1.7 log copies
(range, undetectable to 4.4 log copies) at a median of
58 days posttransplantation (range, 28 to 104 days).
At 1 year posttransplantation, the VLs in the 3 patients
assessed were 1.7, 3.0, and 4.4 log copies.DISCUSSION
This is the largest series assessing the outcome of
alloHCT in HIV-positive patients. Primary engraft-
ment was achieved in most of the evaluable patients;
1 patient who underwentNMA transplantation experi-
enced secondary graft failure. This engraftment pat-
tern seems comparable to that seen in HIV-negative
patients. The cumulative incidences of aGVHD and
cGVHD do not differ significantly from those
expected in HIV-negative patients.
Survival was low in this series, particularly in those
patients who underwent transplantation before 1996.
Major causes of death were regimen-related toxicities
and infections. Among the regimen-related toxicities,
pulmonary toxicity was common, particularly in those
patients receiving high-dose TBI. A high incidence of
pulmonary toxicity may be related to opportunistic
infections pretransplantation. Data on pretransplanta-
tion opportunistic infections were available in 57% of
our patients. Because of the limited sample size, the im-
pact of opportunistic infections on posttransplantation
outcomes could not be assessed. Modern supportive
care strategies and conditioning regimens with lowertoxicity may reduce regimen-related toxicities. The
risk of posttransplantation infections may be greater
in HIV-positive patients compared with HIV-negative
patients, although this increased risk was not evident in
our cohort, in which the infection density was just
slightly greater than 1 infection per patient in the first
100 days posttransplantation. CD4 count and VL data
during the posttransplantation period were available
foronly3patients.These3patients exhibited adecrease
in CD4 count between pretransplantation and 1month
posttransplantation and subsequent slow recovery to.
300/mL at 1 year posttransplantation. The recovery did
not appear to be slower in the HIV-positive patients
than in the HIV-negative patients; in HIV-negative
marrow recipients, CD4 counts typically recover to
. 200/mL by 1 year [32].
Our study is limited by small number of patients
treated in the post-HAART era and incomplete CD4
count and VL data. Nevertheless, survival appears to
be better in the patients treated after 1996 than in
those treated before 1996. This is presumably because
of the effect of better supportive care strategies and the
routine use of HAART, which became standard at
around this time. This study demonstrates that some
patients treated for various malignant and nonmalig-
nant hematologic disorders achieved long-term
disease control. Because of our heterogeneous study
population, drawing conclusions about the efficacy of
this treatment modality for a particular disease is diffi-
cult. The availability of HAART apparently has led to
a trend toward increasing use of autologous transplan-
tation in HIV-positive patients with lymphoma,
although these patients still rarely undergo alloHCT.
This may be related to the hesitancy of physicians to
use this modality because of concerns about high treat-
ment-related mortality (TRM) and lack of published
data. Accumulating data on solid organ transplantation
indicate that transplantation outcomes in HIV-posi-
tive patients are not inferior to those in HIV-negative
patients [33,34]. A recent study using kidney trans-
plantation data from the United Network for Organ
Sharing found comparable graft and patient survival
in 38HIV-positive patients andHIV-negative patients
[34]. Thus, there is increasing debate regarding the
ethical justifications of excluding HIV-positive
patients from transplantation and cancer clinical trials
[35]. Many researchers believe that the situation of
a well-controlled HIV infection is no different from
medical comorbidities requiring regular treatment.
In summary, our data demonstrate that despite
early toxicity because of conditioning regimens and
the risk of opportunistic infections, several patients
achieved prolonged survival. Given the improvements
in supportive care, the availability of conditioning reg-
imens with lower toxicity, and the ability to suppress
HIV VL with currently available medical care,
alloHCT should not be dismissed as a treatment
870 Biol Blood Marrow Transplant 15:864-871, 2009V. Gupta et al.option in HIV-positive patients with hematologic dis-
orders for which alloHCT is considered the therapy of
choice. Prospective studies are needed inHIV-positive
patients to evaluate the efficacy of this modality in
specific diseases and identify optimal transplantation
and antiretroviral strategies.ACKNOWLEDGMENTS
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